Oprozomib is a potent oral tripeptide epoxyketone proteasome inhibitor developed for the treatment of multiple myeloma and various hematological malignancies. By targeting the proteasome, this agent effectively… Read more
Oprozomib is a potent oral tripeptide epoxyketone proteasome inhibitor developed for the treatment of multiple myeloma and various hematological malignancies. By targeting the proteasome, this agent effectively disrupts protein homeostasis within malignant cells, leading to apoptosis and inhibition of tumor growth. This category provides essential pharmaceutical reference standards, including the parent compound and related stable isotope labelled compounds such as Oprozomib-d6. These high-quality reference materials are critical tools for analytical chemists and pharmaceutical researchers who require accurate quantitative analysis during method validation, impurity profiling, and quality control assays. Utilizing stable isotope labelled standards ensures precision in mass spectrometry and chromatographic workflows, allowing laboratories to reliably monitor the purity, stability, and concentration of drug formulations throughout the lifecycle of drug development and rigorous regulatory testing.